Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…